-
The Ernst Vioxx Verdict: A Retrospective Look Into the Jury Room, Part Three
The Ernst v. Merck Jury: On Why Punitive Damages Were Warranted, and How They Arrived at the $229 Million Amount The Association of Trial Lawyers of America ("ATLA"), of which I am a proud…
-
The Ernst Vioxx Verdict: A Retrospective Look Into the Jury Room, Part Two
The Ernst v. Merck Jury: On Merck’s Decision to Market Vioxx Despite Knowing About the Cardiovascular Problems The Association of Trial Lawyers of America ("ATLA"), of which I am a proud member, has compiled…
-
The Ernst Vioxx Verdict: A Retrospective Look Into the Jury Room, Part One
The Ernst v. Merck Jury: On Sending a Message to Merck and Big Pharma The Association of Trial Lawyers of America ("ATLA"), of which I am a proud member, has compiled selected statements made…
-
Scios / J&J to Educate Doctors Regarding Which Patients Should, and Should Not, Receive Natrecor
Guidance to Doctors Prompted by Natrecor Expert Panel or US DOJ Investigation of Sales Tactics? Johnson & Johnson’s Scios unit announced on August 22, 2005 the launch of a new program intended to educate…
-
New Drug Safety Panel Will Mean More FDA Scrutiny of Drugs Already on Market, But Perhaps Not Enough
Congress Should Give FDA Authority to Impose New Labeling Language on Approved Drugs Without Needing Big Pharma’s Permission When Health and Human Services (HHS) Secretary Michael Leavitt was announcing the new Drug Safety Oversight…
-
Upcoming Vioxx Trials: The Fall 2005 Line-up for Merck and Its Lawyers
A Summary of the Vioxx Lawsuits Coming Soon in New Jersey, Texas, and Louisiana As is well-known by now, Merck & Co. lost its first Vioxx trial in a Texas state court last week,…
